HOTH
Hoth Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.80
−2.22%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -29.2%
- EPS
- +29.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -35.2%
- Net income
- -52.3%
- EPS
- +29.7%
- Free cash flow
- -40.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026